drugset

drugset / Trial / NCT00447941

Safety, PK and PD Study in Healthy Male Japanese Subjects

NCT00447941 ↗

Phase 1 Completed 24 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedCrossoverDouble-blindTreatment

Summary

Study assessing pharmacokinetics, pharmacodynamics, safety, and tolerability of oral doses of SCA-136 in healthy male Japanese subjects

Timeline

Start: 2006-06
Primary completion: 2006-08
Completion: 2006-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	vabicaserin	Small molecule	—	Oral

Indications